KalVista gains on Phase II data for oral HAE treatment

KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its oral on-demand protease inhibitor for HAE attacks met its primary endpoint of reducing the use of rescue medication. 

The Phase II trial was a randomized, double-blind, placebo-controlled crossover trial with 53 adult hereditary angioedema (HAE) patients who received a single dose of KVD900 or placebo within one hour of the start of the first attack. During the second attack, the patients received a dose of the alternative crossover treatment. All patients could use a rescue treatment if needed...